Precision Oncology Predicine operates in precision oncology with a liquid biopsy platform (cfDNA and cfRNA) and a portfolio of blood, urine, and tissue assays, presenting cross-sell opportunities to biopharma partners and hospitals seeking minimally invasive diagnostics for treatment selection, monitoring, MRD, and early detection.

Global Partnerships With operations in Silicon Valley, Houston, Shanghai, Singapore, and Boston, Predicine has an established global footprint and collaborative model that can be leveraged to secure multinational trials, regulatory-compliant deployments, and co-development agreements with pharma, CROs, and academic centers.

NGSKit Expansion Recent product launches such as PredicineCARE NGS Kit and the broader PredicineCOMPLETE solution indicate a push toward end-to-end sequencing assays; potential sales; upsell to current customers for additional kits, workflow integrations, and service agreements for clinical studies and diagnostics deployments.

Data & Tech Leveraging Illumina platforms, MySQL, analytics tooling, and web infrastructure positions Predicine to offer integrated data services, cloud-based analytics, and companion diagnostic development support to biopharma partners seeking scalable, data-driven biomarker programs.

Financial Signal With reported revenue in the tens of millions and a mid-market employee base, Predicine presents a manageable growth partner for mid- to large-tier pharma and contract service organizations seeking innovative liquid biopsy capabilities, MRD monitoring, and early-detection assets to expand portfolio offerings.